| Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. | |
| | |
MedLine Citation:
|
PMID: 17982304 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The association between low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and the development of coronary heart disease (CHD) is well established. The management of CHD has traditionally focused on the reduction of LDL cholesterol or on the total lipid profile. Yet, treatment strategies for reducing risk in CHD also requires a focus on increasing low HDL cholesterol, as LDL cholesterol reduction alone is insufficient in preventing CHD events. This article reviews the strategies for targeting HDL cholesterol to optimize outcomes in CHD. |
| | |
Authors:
|
Michael H Davidson |
Related Documents
:
|
20534764 - A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormo... 2859784 - Effect of beta blockers on blood lipid profile. 8321794 - Raising hdl cholesterol with low-dose nicotinic acid and bezafibrate: preliminary exper... 2403244 - Effects of a short-term (4 weeks) protein-sparing modified fast on plasma lipids and li... 6441004 - Optimal lipid content for enteral diets following thermal injury. 16154574 - Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activat... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American heart hospital journal Volume: 5 ISSN: 1541-9215 ISO Abbreviation: Am Heart Hosp J Publication Date: 2007 |
Date Detail:
|
Created Date: 2007-11-05 Completed Date: 2008-02-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101156064 Medline TA: Am Heart Hosp J Country: United States |
Other Details:
|
Languages: eng Pagination: 210-6 Citation Subset: IM |
Affiliation:
|
Pritzker School of Medicine, University of Chicago, Chicago, IL, USA. michaeldavidson@radiantresearch.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
therapeutic use Cardiovascular Diseases / drug therapy* Cholesterol, HDL / drug effects* Clofibric Acid / therapeutic use Dyslipidemias / drug therapy* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Niacin / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 59-67-6/Niacin; 882-09-7/Clofibric Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sex differences in myocardial infarction events between patients with and without conventional risk ...
Next Document: Higher prevalence of cardiovascular events among patients with abnormal atrial depolarization and co...